Safety and efficacy of nivolumab as a second line therapy in metastatic renal cell carcinoma: a retrospective chart review

Scientific paper - Original scientific paper

• Author: Marija Gamulin
• Author: Eric Nham
• Author: Deni Rkman
• Author: Zrna Antunac
• Author: Zrna Golubić
• Author: Robert Likić
• Author's institution: University of Zagreb; School of Medicine; (Department of Internal Medicine)
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Clinical Medical Sciences; Internal Medicine

Abstract (english)

Aim To assess diseases outcomes and tolerability of real-life second-line nivolumab in a series of metastatic renal cell carcinoma (mRCC) patients. ----- Methods This retrospective chart review involved prospectively monitored patients (named patient program) treated with second-line nivolumab for mRCC at the University Hospital Centre Zagreb from February 2016 to March 2018. ----- Results The study enrolled 30 patients, 5 of whom (16.7%) had a complete response. The mean ± standard deviation therapeutic response time to nivolumab treatment was 14.07 ± 8.92 months, with a minimum treatment duration of 2 months and a maximum of 24 months. The median duration of therapy was 17 months (mean: 15.8 months; range: 3-24 months), and 50% (n = 15/30) of patients remained alive at the end of follow up. The most common adverse events associated with nivolumab were fatigue (26.67%; n = 8/30), anemia (10.0%; n = 3/30), adrenal insufficiency (6.67%; n = 2/30: G1 = 1, G2 = 1), grade 2 pneumonitis (6.67%; n = 2/30), grade 2 neuropathy (6.67%; n = 2/30), rash (6.67%; n = 2/30: G1 = 1, G2 = 1), and hepatitis (3.33%; n = 1/30). ----- Conclusion The present study indicates acceptable patient responses and tolerability of nivolumab in mRCC.

• Keywords (english): Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological / adverse effects; Antineoplastic Agents, Immunological / therapeutic use; Carcinoma, Renal Cell / drug therapy; Carcinoma, Renal Cell / pathology; Female; Humans; Kidney Neoplasms / drug therapy; Kidney Neoplasms / pathology; Male; Middle Aged; Nivolumab / adverse effects; Nivolumab / therapeutic use; Retrospective Studies; Treatment Outcome
• Language: english
• Publication type: Scientific paper - Original scientific paper
• Publication status: Published
• Peer review: Peer review
• Publication version: Published version
• Journal title: Croatian Medical Journal
• Numbering: vol. 61, no. 4, pp. 326-332
• p-ISSN: 0353-9504
• e-ISSN: 1332-8166
• DOI: https://doi.org/10.3325/cmj.2020.61.326
• URN:NBN: urn:nbn:hr:105:651557
• Publication: 2020-08-01
• Document URL: http://www.cmj.hr/2020/61/4/32881430.htm
• Type of resource: Text
• Access conditions: Open access
• Created on: 2020-10-28 07:59:40